Bristol-Myers Squibb Company (BMY) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Total Cash From Operating Activities Chart for Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) operating cash flow for FY2025 was USD 14.2B, a -6.8% change from FY2024. Bristol-Myers Squibb Company's operating cash flow grew from USD 1.2B in 1989 to USD 14.2B in 2025 (1089.6% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 0.1%, 10-year CAGR of 21.0%, 20-year CAGR of 10.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$127.71B
Implied Share Price
$62.48
Enterprise Value
$159.47B
Revenue (TTM)
$50.03B
EBITDA
$18.78B
Profit Margin
18.47%
Trailing P/E
13.76
Forward P/E
9.35
Price/Book (MRQ)
5.62
Price/Sales (TTM)
2.55
EV/EBITDA
9.48
EV/Revenue
3.24
Dividend Yield
1.03%
Book Value
$9.07
Free Cash Flow (FY2025)
$12.85B
Free Cash Flow Yield
10.06%

Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.